Shanghai Henlius Biotech

This study tests whether adding a new experimental drug (HLX22) to the standard two-drug treatment can help people with advanced HER2-positive stomach or gastroesophageal cancer live longer without their cancer growing. About 550 adults who have not had prior treatment for their …

This early-phase study tests a new drug called HLX3901 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 138 adults aged 18 to 75 will take part.

This study tests a new drug called HLX43 in 70 people with advanced nasopharyngeal cancer that has come back or spread and did not respond to or could not tolerate standard second-line treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. …

This study tests a new drug called HLX43 in 60 people with advanced stomach or gastroesophageal junction cancer that has spread. The drug targets a protein on cancer cells to deliver a toxin directly. The goal is to find the best dose and see if it shrinks tumors safely.

This study tests a new drug called HLX17, which is similar to the cancer drug Keytruda. It is for people whose non-small cell lung cancer, melanoma, or kidney cancer has been surgically removed. The goal is to see how the body processes HLX17 compared to Keytruda, and to check fo…

This study tests a new drug called HLX43 in about 190 women with cervical or ovarian cancer that has come back or spread and did not respond to standard first treatment. The drug is designed to target and kill cancer cells. The goal is to see if it can shrink tumors and slow dise…

This study tests a new drug (HLX79) combined with an existing antibody treatment (rituximab) in people with active kidney inflammation called glomerulonephritis. The goal is to see if the combination is safe and helps control the disease better than rituximab alone. About 24 adul…

This early-phase study tests a new drug called HLX42 in people with advanced solid tumors, including non-small cell lung cancer, who have run out of standard options. The main goal is to check safety and find the right dose. About 102 adults aged 18-75 will take part.

This study is for people with advanced or metastatic solid tumors, including non-small cell lung cancer, who have not responded to other treatments. It tests a combination of two drugs: HLX43 (an antibody-drug conjugate targeting PD-L1) and serplulimab (an immunotherapy). The goa…

This study tests a new drug called HLX43 for people with advanced esophageal cancer that has come back or spread after standard first treatment. The drug is designed to find and attack cancer cells while limiting harm to healthy cells. About 102 participants will receive the drug…

This study tests a new drug called HLX43 in 60 adults with advanced colorectal cancer that has stopped responding to standard treatments. The drug is designed to attach to a protein on cancer cells and deliver a toxic payload to kill them. The main goal is to find the best dose a…

This study tests a copycat version (HLX13) of an approved cancer drug (YERVOY) in adults with advanced liver cancer that cannot be removed by surgery. About 246 people will receive either the copycat or the original drug to see if they work similarly. The goal is to control the c…

This study tests whether combining two experimental drugs (HLX22 and HLX87) works better than standard treatment for people with HER2-positive breast cancer that has returned or spread. About 706 adults will take part. The main goals are to see if tumors shrink and how long the c…

This study tests a new drug called HLX37 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is a bispecific antibody that targets two proteins (PD-L1 and VEGF) involved in tumor growth. The main goals are to check the drug's safety, find the r…

This early-phase study tests a new drug called HLX43 in people with advanced or spreading solid tumors that haven't responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 340 adults aged 18 to 7…

This study tests a new combination of two drugs (HLX43 and serplulimab) given before surgery to people with non-small cell lung cancer. The goal is to see if the drugs can shrink tumors and improve treatment results. About 60 adults with stage II-IIIB lung cancer will participate…

This study tests an experimental drug called HLX43 in people whose head and neck cancer has returned or spread to other parts of the body. The drug works by attaching a cancer-killing agent to an antibody that targets a protein (PD-L1) on tumor cells. About 167 adults aged 18 to …